Web Analytics

3 Latest Announced Rounds

  • $10,500,000
    Series A

    6 Investors

    Chemical Manufacturing
    Nov 15th, 2024
  • $3,000,000
    Pre-Seed

    1 Investors

    Software Development
    Nov 15th, 2024
  • $1,600,000
    Pre-Seed

    3 Investors

    Software Development
    Nov 15th, 2024
$1,512.09M Raised in 74 Funding Rounds in the past 7 Days - View All

Funding Round Profile

Nature's Toolbox, Inc. (NTx)

start up
Mexico - Rio Rancho, New Mexico
  • 17/11/2023
  • Series B
  • $47,500,000

Nature's Toolbox, Inc. (NTx) is advancing the healthcare industry with their cutting-edge biomanufacturing solutions. NTx, based in Rio Rancho, New Mexico, is using innovative systems like NTxpress® and NTxscribe® to create life-saving medicines in an eco-friendly and sustainable way. Their proprietary biomanufacturing process uses hollow fiber bioreactors to support the increasing demand for mRNA-based vaccines and protein therapeutics. This easily scalable process enables NTx’s partners to increase production and streamline operations to meet changing global demands. To learn more about their game-changing approach, visit their website at https://www.ntxbio.com.


Related People

Jamie CoffinFounder

Jamie Coffin United States - Frisco, Texas

As the CEO and Board Director of Nature's Toolbox (NTx), I lead a visionary company that has re-imagined how biomanufacturing can be done, using a proprietary, continuous flow, cell-free system that enables global access to the next generation of vaccines and therapeutics. With over 20 years of experience in the healthcare and life sciences industries, I have a strong track record of selling, developing, and delivering highly sophisticated hardware, software, and professional services solutions across various domains, such as genomics, chemistry, informatics, and medical imaging.

Prior to joining NTx in February 2023, I served as the President and Chief Operating Officer of Sema4, a health information company that offers advanced genome-based diagnostics and predictive models of complex disease. I grew the company from a Mount Sinai Health System venture to a leading player in the field of personalized medicine, leveraging the power of data, analytics, and cloud computing. I also have extensive experience in general management, sales leadership, and business development, having successfully scaled and exited two private equity owned companies in the ambulatory surgical and physical therapy spaces. I am passionate about the role of technology in advancing the healthcare and life sciences sector, and I hold a PhD in Chemistry from the University of Arkansas and was a Fulbright College Dissertation Fellow at the University of Cambridge.